How Are Microba Life Sciences (ASX:MAP) Shares Faring After a 10% Drop?

Sonal Goyal

22 October 2026 05:52 PM AEDT

How Are Microba Life Sciences (ASX:MAP) Shares Faring After a 10% Drop?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Microba Life Sciences (ASX:MAP) shares were down 10.00% at $0.036 during the 22 October 2026 trading session.
An announcement dated 21 October 2026 set revised Merger terms with Genetic Signatures: Microba holders 60%, GSS holders 40%.
The proposed merger remains subject to due diligence, binding documentation and Shareholder and Court approvals.

Microba Life Sciences Limited (ASX:MAP) shares were down 10.00% at $0.036 during the Trading session on 22 October 2026, at the time of the data. During the trading session on 22 October 2026, the S&P/ASX 200 stood at 8,792.20, down 0.44%, while the All Ordinaries stood at 8,916.20, down 0.45%. Microba is a microbiome health company that aims to deliver clinical-grade microbiome tests. In an ASX announcement dated 21 October 2026, released jointly with Genetic Signatures Limited (ASX:GSS), the two companies updated the commercial terms of their proposed merger, under which Microba shareholders would hold 60% of the enlarged GSS on implementation.

About the Company

Microba Life Sciences is listed on the Australian Securities Exchange under the ticker MAP. The company describes itself as being at the forefront of microbiome health and human care. Its chair, Pasquale Rombola, is named as the investor contact in the latest announcement. The proposed merger partner, Genetic Signatures, operates from Newtown, New South Wales.

Business Overview

Microba states that its vision is to deliver clinical-grade microbiome tests that help people live healthier lives, supported by what it describes as world-leading science, insights and collaboration tools.

Its proposed merger partner, Genetic Signatures, is a specialist molecular diagnostics company. It develops and commercialises the proprietary 3base platform technology and designs and manufactures real-time PCR-based products for the routine detection of infectious diseases under the EasyScreen brand. Its target markets are major hospital and pathology laboratories undertaking infectious disease screening.

Revised Merger Terms

In the announcement dated 21 October 2026, the companies said they had agreed in principle to revised terms. Microba shareholders would hold 60% of GSS on implementation, compared with approximately 67% previously, while existing GSS shareholders would hold 40%, up from approximately 33%.

GSS would acquire all issued securities in Microba through concurrent Court-approved share and option schemes of arrangement. The final number of GSS shares to be issued will be set by a scheme formula: 0.6 multiplied by the total GSS shares on issue divided by 0.4, then divided by the total Microba shares on issue, each measured at the scheme record date.

Placement and Dilution Treatment

The announcement noted that a Placement announced by Microba earlier on 21 October 2026 would not be dilutive to GSS shareholders by operation of the scheme formula. All other material terms of the proposed merger, including its strategic rationale, were reported as unchanged.

An addendum to the GSS Notice of Annual General Meeting, which includes an additional resolution to approve the merger, was with ASX for review and expected to be released shortly. It will summarise the key terms of the proposed merger.

Approvals and Process

The GSS Board continues to unanimously recommend that its shareholders vote in favour of the resolution to approve the issue of securities at the company's Annual General Meeting on 16 November 2026. GSS and Microba expect to execute the scheme implementation deed after receiving that approval.

The proposed merger remains subject to approval by both GSS shareholders and Microba shareholders and option holders, as well as the Court.

Related Sector Context

Microbiome science and molecular diagnostics sit within the broader healthcare and life sciences field, where companies develop tests and tools used by clinicians and pathology laboratories. Transactions between listed healthcare companies are commonly structured as schemes of arrangement that require shareholder and Court approval. With the S&P/ASX 200 down 0.44% and the All Ordinaries down 0.45%, the broader market also traded lower during the session.

Risks to Weigh In

The announcement states that GSS and Microba are yet to enter into binding documentation and that the transaction terms remain subject to ongoing due diligence. The revised terms will be recorded in the scheme implementation deed, which is not yet executed.

Approval of the addendum by ASX, the GSS shareholder vote, the votes of Microba shareholders and option holders and the Court process are all still to be obtained. The announcement also cautions that the merger may not be implemented on the revised terms or at all, and that its timing and the number of securities to be issued may change.

Catalysts on Watch

Dates and steps referenced include the expected release of the addendum to the GSS Notice of Annual General Meeting, the GSS Annual General Meeting on 16 November 2026, execution of the scheme implementation deed following shareholder approval, and later Microba shareholder, option holder and Court approvals. The final share numbers will be determined by the scheme formula at the scheme record date, once the number of shares on issue in each company is known.

Putting It Together

Microba Life Sciences traded lower during the 22 October 2026 session, at $0.036. The announcement dated 21 October 2026 revised the merger split with Genetic Signatures to 60% and 40%, with other material terms unchanged and several approvals still required.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.